UPDATE: FOX Sports’ Ken Rosenthal reports that Padres left-hander Marc Rzepczynski is the reliever who was claimed off revocable waivers by the Mets. It’s unclear how long the two sides have to complete a deal.
Rzepczynski was just acquired from the Indians last month. The 29-year-old owns a mediocre 4.88 ERA in 60 appearances this season, but he has 33 strikeouts in 27 2/3 innings and the highest ground ball rate of his career. With his history of keeping left-handed batters in check, you can see why the Mets would consider taking a chance on him. He’s making $2.4 million this season and will be arbitration-eligible for the fourth and final time this winter.
3:10 p.m. ET: FOX Sports’ Ken Rosenthal adds that the Mets have put in a waiver claim on a reliever. The team with the reliever can either let him go to the Mets, negotiate a trade, or pull him back off waivers.
2:59 p.m. ET: MLB’s waiver trade deadline is coming up on Tuesday and Adam Rubin of ESPN New York reports that the first-place Mets are “making progress” on acquiring a reliever.
While it’s no sure thing that a deal will ultimately come together, Rubin hears that the Mets are having “tangible talks.” The team has already added Tyler Clippard and Eric O’Flaherty in separate deals with the Athletics over the past month. While Clippard has settled in as the primary set-up man for closer Jeurys Familia, O’Flaherty has allowed 10 runs on 13 hits and one walk over six innings with his new club. The Mets have gotten next to nothing out of the likes of Jenrry Mejia, Jerry Blevins, Bobby Parnell, and Vic Black this season, so the bridge to the late innings is a bit shaky at the moment.
Acquiring a left-handed specialist would be ideal, but it will be interesting to see if a quality arm makes it to them through waivers. There’s incentive for other teams to put in a claim first, either out of legitimate need or to block.
Jenrry Mejia just finished serving an 80-game suspension for Stanozolol, a performance-enhancing drug. And he apparently hasn’t quit the stuff. Via CBS Sports’ Jon Heyman …
This time it’s for both Stanozolol and Boldenone. Monday night’s Tyler Clippard trade is suddenly looking even more crucial for the Mets, who currently sit two games back of the Nationals in the NL East.
Mejia had registered 7 1/3 scoreless innings of relief this season for New York.
After upgrading their lineup over the weekend with the additions of Juan Uribe and Kelly Johnson, the Mets addressed the back-end of their bullpen tonight by acquiring reliever Tyler Clippard from the Athletics for prospect right-hander Casey Meisner. Ken Davidoff of the New York Post reports that Oakland is including $1 million in the deal, so the Mets will be responsible for around $2 million of Clippard’s remaining salary.
Clippard has functioned as Oakland’s primary closer this season, posting a 2.79 ERA and 38/21 K/BB ratio in 38 2/3 innings while going 17-for-21 in save chances. He’ll presumably move back into a set-up role in New York and has a chance to form a potent late-inning duo with closer Jeurys Familia. While Clippard’s walks are up a bit this season, he has been one of the game’s better relievers dating back to 2009. Bobby Parnell hasn’t shown his pre-Tommy John surgery form quite yet and Jenrry Mejia isn’t eligible to pitch in the postseason, so it’s a smart move for the Mets. It also helps to keep Clippard away from the first-place Nationals, who reportedly had interest in bringing him back.
Meisner, a third-round pick from 2013, owns a 2.89 ERA with 7.9 K/9 and 2.6 BB/9 over 35 starts and six relief appearances in the minors. The 20-year-old has split this season between Class A Savannah and High-A St. Lucie. He could be a useful piece down the road for Oakland, but the Mets still have plenty of prospect depth if they decide to pick up another bat in the coming days.